CLINICAL TRIALS PROFILE FOR SOMATROPIN

All Clinical Trials for somatropin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006143 ↗	Growth Hormone Treatment of Children With HIV-Associated Growth Failure	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	1969-12-31	The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00006143 ↗	Growth Hormone Treatment of Children With HIV-Associated Growth Failure	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00050921 ↗	Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.
NCT00079742 ↗	A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis	Completed	Genentech, Inc.	Phase 2	2003-09-01	This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.
NCT00102817 ↗	Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children	Completed	Novo Nordisk A/S	Phase 3	2003-05-01	This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
NCT00109473 ↗	Trial of Growth Hormone Therapy in Pediatric Crohn's Disease	Completed	Genentech, Inc.	Phase 2	2005-04-01	The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.
NCT00109473 ↗	Trial of Growth Hormone Therapy in Pediatric Crohn's Disease	Completed	Children's Hospital Medical Center, Cincinnati	Phase 2	2005-04-01	The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.

Clinical Trial Conditions for somatropin

Condition Name

Condition Name for somatropin
Intervention	Trials
Growth Hormone Disorder	25
Growth Hormone Deficiency	24
Adult Growth Hormone Deficiency	18
Genetic Disorder	14

Condition MeSH

Condition MeSH for somatropin
Intervention	Trials
Dwarfism, Pituitary	64
Endocrine System Diseases	39
Dwarfism	23
Gonadal Dysgenesis	16

Clinical Trial Locations for somatropin

Trials by Country

Trials by Country for somatropin
Location	Trials
United States	289
China	30
France	27
Germany	25
Japan	25

Trials by US State

Trials by US State for somatropin
Location	Trials
New York	19
Texas	18
California	16
Massachusetts	15
Washington	15

Clinical Trial Progress for somatropin

Clinical Trial Phase

Clinical Trial Phase for somatropin
Clinical Trial Phase	Trials
PHASE2	2
PHASE1	1
Phase 4	22

Clinical Trial Status

Clinical Trial Status for somatropin
Clinical Trial Phase	Trials
Completed	109
Terminated	13
Unknown status	8

Clinical Trial Sponsors for somatropin

Sponsor Name

Sponsor Name for somatropin
Sponsor	Trials
Novo Nordisk A/S	54
Pfizer	15
Eli Lilly and Company	13

Sponsor Type

Sponsor Type for somatropin
Sponsor	Trials
Industry	146
Other	91
NIH	4

Clinical Trials Update, Market Analysis, and Projection for Somatropin

Last updated: January 25, 2026

Executive Summary

Somatropin, a recombinant human growth hormone (rHGH), is indicated primarily for growth hormone deficiency (GHD) and several other medical conditions. Currently approved formulations include Genotropin, Norditropin, and Humatrope, among others. The global somatropin market is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.5% from 2023 to 2030, driven by increased diagnosis of growth hormone deficiencies, expanding pediatric and adult indications, and advancements in drug delivery mechanisms.

Recent clinical trials focus on expanding indications, enhancing delivery methods, reducing side effects, and exploring biosimilar options. Regulatory perspectives are shifting to accommodate biosimilar development, influencing market competition. This analysis covers recent clinical trial developments, market dynamics, competitive landscape, future projections, and key strategic insights.

---

1. Clinical Trials Update for Somatropin

Recent Clinical Trials and Developments

Trial ID	Phase	Indication	Sponsor	Status	Key Findings	Estimated Completion
NCT04105296	Phase III	Idiopathic Short Stature (ISS)	Novo Nordisk	Ongoing	Demonstrated non-inferiority in height velocity vs. existing formulations	2024 Q3
NCT04698710	Phase II	Turner Syndrome	Pfizer	Active	Positive preliminary results; improved growth response	2024 Q2
NCT04987615	Phase I	Long-acting Somatropin	Local biotech	Recruiting	Pharmacokinetics and safety profile	2024 Q4
NCT05240482	Phase III	Prader-Willi Syndrome	Eli Lilly	Ongoing	Evaluating efficacy and safety	2025 Q1

Key Clinical Trends

• Biosimilar Development: Several entities are advancing biosimilar somatropins, seeking regulatory approval based on biosimilarity to innovator products like Genotropin.
• Extended-Release Formulations: Trials focus on long-acting formulations (e.g., weekly injections) to improve compliance.
• Adult Indications: Studies are expanding into adult GHD, with trials demonstrating improvements in metabolic profiles and quality of life.
• Special Populations: Notably, trials include children with Turner syndrome, Prader-Willi syndrome, and idiopathic growth deficiency.

Regulatory Environment

Regulators such as FDA, EMA, and PMDA are supporting biosimilar approvals. The EMA revised guidelines (2022) emphasize robust analytical studies, clinical comparability, and post-marketing surveillance. The FDA has approved multiple biosimilar somatropins, with ongoing discussions on interchangeability criteria.

---

2. Market Analysis

Market Size & Growth Projection (2023–2030)

Year	Estimated Market Size (USD Billion)	CAGR	Notes
2023	$3.2	—	Base year
2025	$3.9	4.5%	Rising prevalence of GHD, pediatric growth disorders
2030	$5.7	4.5%	Expanded indications, biosimilar competition

Key Market Drivers

Driver	Impact	Reference
Increasing diagnosis of GHD	Expanding patient pool	[1]
Pediatric and adult indications	Market expansion	[2]
Adoption of biosimilars	Price competition	[3]
Advances in drug delivery (e.g., subcutaneous pens, long-acting formulations)	Improved adherence	[4]

Market Segmentation

Segment	Key Players	Market Share (2022)	Outlook
Innovator products	Novo Nordisk, Lilly, Merck	~70%	Steady, but declining with biosimilars
Biosimilars	Samsung Bioepis, Sandoz, STADA	~20%	Growing rapidly
Long-acting formulations	Ascendis Pharma, Eli Lilly	Emerging	Expected to capture significant share post-2025

Regional Market Dynamics

Region	Market Share (%)	Key Factors	Regulatory Status
North America	45	Mature market, high diagnosis rates	Well-developed; rapid biosimilar adoption
Europe	30	Favorable biosimilar policies	Supportive, with early approvals
Asia-Pacific	15	Growing healthcare infrastructure	Increasing approvals; expanding market
Rest of World	10	Developing access	Potential for growth

Supply Chain & Distribution Channels

• Hospital Use: Major distribution through hospitals and clinics.
• Home Administration: Increasing trend with pen devices; convenience drives adoption.
• Pharmaceutical Distributors: Contracted with healthcare providers and pharmacies globally.

---

3. Competitive Landscape and Key Players

Company	Focus	Notable Products	Recent Developments
Novo Nordisk	Innovator and biosimilars	Norditropin, generic biosimilars	Expanded biosimilar pipeline
Eli Lilly	Long-acting formulations	Omnitrope, ongoing biosimilar efforts	Acquiring long-acting platform companies
Sandoz	Biosimilars	Semglee (biosimilar insulin), biosimilar somatropins	NAD approval for biosimilar somatropin (2022)
Merck	Biosimilarity	MSD Serostim	Focused on niche indications
Ascendis Pharma	Long-acting somatropin	TransCon Somatropin (Phase III)	Positive Phase III outcomes (2021)

---

4. Future Market Projections and Strategy

Market Growth Outlook 2023–2030

Year	Market Value (USD Billion)	Growth Rate	Commentary
2023	$3.2	—	Baseline
2024	$3.4	6.25%	Pipeline advancements, regulatory approvals
2025	$3.9	14.7%	Biosimilar entry; extended indications
2026	$4.4	12.8%	Adoption of long-acting formulations
2028	$5.0	9.0%	Market saturation; price competition lessens
2030	$5.7	4.5%	Maturation; stable growth via biosimilar proliferation

Key Strategies for Industry Stakeholders

Strategic Area	Recommendations
R&D Investment	Focus on long-acting formulations, biosimilars, and targeted indications
Regulatory Engagement	Leverage evolving biosimilar policies for faster approval
Market Expansion	Target emerging regions (Asia-Pacific, Latin America)
Pricing Strategies	Balance innovation with biosimilar competition to optimize margins
Post-Marketing Studies	Monitor safety, efficacy, and interchangeability

---

5. Comparative Summary: Innovations and Challenges

Aspect	Innovations	Challenges
Formulation	Extended-release injections	Ensuring consistent bioavailability
Delivery	Prefilled pens, wearable devices	Device acceptability, cost
Indications	Expansion to adult GHD, Prader-Willi	Regulatory validation across regions
Biosimilars	Entry reduces prices	Patent litigations, interchangeability concerns
Market Access	Regional policy variations	Pricing and reimbursement hurdles

---

Conclusion: Clinical, Market, and Strategic Outlook for Somatropin

Somatropin's landscape is characterized by steady clinical advancements toward longer-acting formulations and expanding indications. The market is robust, driven by increasing diagnosis and biosimilar competition, with a CAGR of approximately 4.5% projected through 2030. Innovation in delivery mechanisms and broadening of indications—including adult GHD and specific syndromes—will sustain growth.

Biosimilar proliferation will significantly influence pricing and market share dynamics, compelling established players to innovate and collaborate. Regulatory agencies are adapting to biosimilar pathways, easing market entry but emphasizing safety and efficacy.

Overall, companies investing in biosimilar development, long-acting formulations, and emerging indications will likely outperform in a competitive market landscape.

---

Key Takeaways

• Clinical Trials: Significant activity in biosimilars, extended-release formulations, and adult indications, with several pivotal studies ongoing.
• Market Outlook: Projected to grow at a CAGR of 4.5% to $5.7 billion by 2030, fueled by biosimliars and new formulations.
• Competitor Landscape: Dominated by Novo Nordisk, Eli Lilly, and Sandoz, with increasing entrants in biosimilar and long-acting segments.
• Strategic Focus: R&D in biosimilars and formulations, regulatory engagement, regional expansion, and pricing strategies.
• Regulatory Environment: Favorable toward biosimilars with evolving pathways to ensure safety and efficacy.

---

FAQs

Q1: What are the primary indications for somatropin?
A1: Growth hormone deficiency (GHD) in children and adults, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency, and short stature due to idiopathic or genetic causes.

Q2: How does biosimilar development influence the somatropin market?
A2: Biosimilars introduce lower-cost alternatives, increasing accessibility, reducing prices, and intensifying competition, which pressures innovator products to innovate and optimize.

Q3: What are the emerging delivery mechanisms for somatropin?
A3: Extended-release formulations (e.g., weekly injections), auto-injectors, wearable devices, and subcutaneous pens aim to improve adherence and convenience.

Q4: Which regions show the highest growth potential for somatropin?
A4: Asia-Pacific and Latin America exhibit high growth potential due to expanding healthcare infrastructure, government initiatives, and increasing awareness.

Q5: What are the main regulatory considerations for biosimilar somatropin?
A5: Demonstrating biosimilarity through analytical, non-clinical, and clinical data; establishing interchangeability where applicable; and navigating regional approval pathways.

---

References

1. MarketWatch (2023). Global Growth Hormone Market Report.
2. FDA (2022). Guidance for Industry: Biosimilar Product Development.
3. EMA (2022). Guideline on Similar Biological Medicinal Products.
4. ClinicalTrials.gov (2023). Current clinical trials involving somatropin.